As of 2025-07-20, the EV/EBITDA ratio of Altimmune Inc (ALT) is -2.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 281.82 mil USD. Altimmune's TTM EBITDA according to its financial statements is -97.96 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 13.6x | 13.2x |
| Forward P/E multiples | 20.5x - 42.4x | 31.4x |
| Fair Price | (24.15) - (15.82) | (26.33) |
| Upside | -692.0% - -487.7% | -745.3% |
| Date | EV/EBITDA |
| 2025-07-18 | -2.88 |
| 2025-07-17 | -2.85 |
| 2025-07-16 | -2.96 |
| 2025-07-15 | -2.96 |
| 2025-07-14 | -3.03 |
| 2025-07-11 | -2.93 |
| 2025-07-10 | -3.14 |
| 2025-07-09 | -3.42 |
| 2025-07-08 | -3.29 |
| 2025-07-07 | -3.17 |
| 2025-07-03 | -3.44 |
| 2025-07-02 | -3.56 |
| 2025-07-01 | -3.00 |
| 2025-06-30 | -2.70 |
| 2025-06-27 | -2.40 |
| 2025-06-26 | -2.49 |
| 2025-06-25 | -5.88 |
| 2025-06-24 | -5.45 |
| 2025-06-23 | -5.29 |
| 2025-06-20 | -5.32 |
| 2025-06-18 | -5.11 |
| 2025-06-17 | -5.20 |
| 2025-06-16 | -5.19 |
| 2025-06-13 | -5.23 |
| 2025-06-12 | -5.42 |
| 2025-06-11 | -4.91 |
| 2025-06-10 | -5.08 |
| 2025-06-09 | -4.43 |
| 2025-06-06 | -4.15 |
| 2025-06-05 | -4.02 |
| 2025-06-04 | -4.04 |
| 2025-06-03 | -3.99 |
| 2025-06-02 | -3.89 |
| 2025-05-30 | -3.99 |
| 2025-05-29 | -4.14 |
| 2025-05-28 | -4.04 |
| 2025-05-27 | -4.06 |
| 2025-05-23 | -4.23 |
| 2025-05-22 | -4.28 |
| 2025-05-21 | -4.13 |
| 2025-05-20 | -4.34 |
| 2025-05-19 | -4.05 |
| 2025-05-16 | -4.12 |
| 2025-05-15 | -4.28 |
| 2025-05-14 | -4.22 |
| 2025-05-13 | -4.27 |
| 2025-05-12 | -4.48 |
| 2025-05-09 | -4.13 |
| 2025-05-08 | -4.30 |
| 2025-05-07 | -3.94 |